Generation of robust resident memory T cells in barrier tissues through skin vaccination

摘要 由2019年NCoV病毒引起的下呼吸道疾病CoVID 19是最新一种引起 人类的流行性疾病。此前，SARS和MERS都是由相关病毒引起的，它们的出现和衰落 像流行病一样休眠。贝塔冠状病毒利用同源“刺突”蛋白结合哺乳动物细胞进入 和感染，大多数疫苗正在研制中，以产生针对独特的2019年NCoV的中和抗体 斯派克蛋白。相反，我们正试图创造一种基于T细胞“通用”的贝塔冠状病毒疫苗 免疫，使用所有已知冠状病毒之间保守的蛋白质作为免疫原。这些蛋白质， 由MVA载体表达并通过表皮破裂传递，应提供广泛和持久的 对过去、现在和未来的贝塔冠状病毒威胁的肺免疫。

SUMMARY COVID 19, the lower respiratory disease caused by the 2019 nCov virus, is the latest betacoronavirus to cause epidemic disease in humans. Previously, SARS and MERS, both cause by related viruses, emerged and fell dormant as epidemics. Betacoronaviruses use homologous “Spike” proteins to bind mammalian cells for entry and infection, and most vaccines are being built to generate neutralizing antibodies to the unique 2019 nCov Spike protein. In contrast, we are trying to create a “universal” betacoronavirus vaccine base on T cell immunity, using proteins conserved between all known coronaviruses as immunogens. These proteins, expressed by MVA vectors and delivered by epidermal disruption, should provide broad and durable pulmonary immunity to past, present, and future betacoronavirus threats.